Sensory Restriction Simulation Training for Nursing Student Empathy and Communication (GENE)

September 21, 2026 updated by: Volkan Gokmen

The Effect of the Reality-Integrated Quality Education (GENE) Approach With Sensory Restriction Simulations on Nursing Students' Empathy, Communication, and Patient-Centered Care Skills

This study evaluates the effect of the Reality-Integrated Quality Education (GENE) approach, an educational intervention using sensory restriction simulations (vision, hearing, speech, and movement restriction), on empathy, communication skills, patience, psychological resilience, and patient-centered care competency among third-year nursing students. Sixty nursing students will be randomly allocated to an experimental group (n=30), who will complete a single 30-45 minute GENE simulation session, or a control group (n=30), who will receive standard theoretical empathy education without the simulation component. Outcomes will be assessed immediately before and after the session using the Turkish versions of the Jefferson Scale of Empathy - Nursing Student (JSE-NS), a Communication Skills Inventory, a Patience Scale, the Brief Resilience Scale, and a Patient-Centered Care Competency Scale. The investigators hypothesize that participation in the GENE sensory restriction simulations will produce greater short-term gains in empathy, communication, patience, resilience, and patient-centered care competency than theoretical education alone.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Empathy, effective communication, and patient-centered care are core competencies for nursing practice, and are traditionally taught through classroom-based theoretical instruction. Sensory restriction simulation is proposed as an experiential teaching strategy in which learners temporarily experience a restriction analogous to a patient's sensory or functional limitation, with the aim of building experiential understanding rather than only conceptual knowledge.

This study uses a quasi-experimental, randomized, pretest-posttest, parallel-group design to evaluate the Reality-Integrated Quality Education (GENE) approach in a single center: the Nursing Department of Agri Ibrahim Cecen University. A pool of 60 third-year nursing students will be randomly allocated to an experimental group (n=30) or a control group (n=30).

The experimental group will complete the GENE model, a four-stage sensory restriction simulation sequence lasting approximately 30-45 minutes in total, comprising sequential simulated restriction of vision, hearing, speech, and movement, each paired with simulated patient-care tasks and structured post-simulation debriefing and feedback (recorded via a post-simulation feedback form). The control group will receive standard theoretical education on empathy and patient-centered care without the simulation component. This is an educational/behavioral intervention rather than a drug, biologic, or device intervention; the study's primary purpose is therefore classified as "Other" (educational intervention effectiveness) rather than treatment, prevention, diagnostic, or supportive care.

Primary and secondary outcomes are assessed once before and once after the session (same day) using the following instruments, all administered in their validated Turkish-language versions: the Jefferson Scale of Empathy - Nursing Student (JSE-NS) for empathy; a Communication Skills Inventory; a Patience Scale; the Brief Resilience Scale; and a Patient-Centered Care Competency Scale (HMBY). An application/intake form (Participant Introduction Form) is used to record participant demographic and background characteristics before randomization.

Planned statistical analysis will use Statistical Package for the Social Sciences (SPSS, version 29). Normality of distributions will be assessed with the Shapiro-Wilk test. Depending on distributional assumptions, within-group pre-post changes and between-group (experimental vs. control) comparisons will be analyzed using repeated-measures analysis of variance (ANOVA) or, for non-normally distributed data, the Wilcoxon signed-rank test and Mann-Whitney U test, with Bonferroni correction applied for multiple comparisons. Effect sizes will be calculated and reported alongside p-values.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
      • Ağrı, Turkey (Türkiye)
        • Agri Ibrahim Cecen University Faculty of Health Sciences
        • Contact:
        • Principal Investigator:
          • Volkan Gokmen, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Currently enrolled as a third-year nursing student in the Nursing Department of Agri Ibrahim Cecen University
  • Voluntary agreement to participate and provide informed consent

Exclusion Criteria:

  • Declining to provide informed consent
  • Not currently enrolled as a third-year nursing student in the Nursing Department of Agri Ibrahim Cecen University

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: GENE Sensory Restriction Simulation Group

Participants complete the GENE model: a single 30-45 minute sequence of four sequential sensory restriction simulations (vision, hearing, speech, and movement restriction), each paired with simulated patient-care tasks, followed by structured debriefing and feedback.
Behavioral: GENE Sensory Restriction Simulation Training

A single 30-45 minute educational simulation session consisting of four sequential sensory restriction stages (vision, hearing, speech, and movement restriction), each combined with simulated patient-care tasks, followed by structured debriefing and feedback using a post-simulation feedback form.
Active Comparator: Control Group

Participants receive standard theoretical education on empathy and patient-centered care, without the GENE sensory restriction simulation component.
Behavioral: Standard Theoretical Empathy Education

Standard classroom-based theoretical education on empathy and patient-centered care, without the GENE sensory restriction simulation component.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in Empathy Level (JSE-NS)
Time Frame: Baseline (immediately before the session) and immediately after the session (same day)

Change in empathy from before to immediately after the session, measured with the Turkish version of the Jefferson Scale of Empathy - Nursing Student (JSE-NS). Higher scores indicate greater empathy.
Baseline (immediately before the session) and immediately after the session (same day)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in Communication Skills
Time Frame: Baseline (immediately before the session) and immediately after the session (same day)

Change in communication skills from before to immediately after the session, measured with the Turkish version of the Communication Skills Inventory. Higher scores indicate better communication skills.
Baseline (immediately before the session) and immediately after the session (same day)
Change in Patience
Time Frame: Baseline (immediately before the session) and immediately after the session (same day)

Change in patience from before to immediately after the session, measured with the Turkish version of the Patience Scale. Higher scores indicate greater patience.
Baseline (immediately before the session) and immediately after the session (same day)
Change in Psychological Resilience
Time Frame: Baseline (immediately before the session) and immediately after the session (same day)

Change in psychological resilience from before to immediately after the session, measured with the Turkish version of the Brief Resilience Scale. Higher scores indicate greater resilience.
Baseline (immediately before the session) and immediately after the session (same day)
Change in Patient-Centered Care Competency (HMBY)
Time Frame: Baseline (immediately before the session) and immediately after the session (same day)

Change in patient-centered care competency from before to immediately after the session, measured with the Patient-Centered Care Competency Scale (HMBY). Higher scores indicate greater competency.
Baseline (immediately before the session) and immediately after the session (same day)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Volkan Gokmen

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Volkan Gokmen, PhD, Agri Ibrahim Cecen University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • AICU-GENE-2026
  • TUBITAK 2209-A (2025 Cycle) (Other Grant/Funding Number: The Scientific and Technological Research Council of Turkey (TUBITAK))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings